ReviewCurrent neurology and neuroscience reports2018
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
Review in Current neurology and neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Annals of the rheumatic diseases · 2021Guideline
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.Journal for immunotherapy of cancer · 2019Pooled it
- Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.Cancer metastasis reviews · 2026Review
- Successful Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept.Clinical case reports · 2026Article
- Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report.Frontiers in immunology · 2026Article
- Case Report: Immune checkpoint inhibitor-induced myositis/myocarditis with myasthenia gravis-like symptoms in a colon cancer patient with suspected thymic metastasis.Frontiers in oncology · 2026Article
- Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis.Frontiers in cardiovascular medicine · 2026Article
- Incidence and outcomes of neuromuscular immune-related adverse events in head and neck cancer patients treated with checkpoint inhibitors.Scientific reports · 2025Article
- Myocarditis and Myasthenia Gravis Induced by Camrelizumab in a Patient With Metastatic B2 Thymoma: A Case Report.Thoracic cancer · 2025Article
- Pembrolizumab-induced myasthenia gravis: A rare immune-related adverse event in a patient treated for bladder cancer.Urology case reports · 2025Article
- Esophageal Dysfunction in Immune Checkpoint Inhibitor-related Myositis.Internal medicine (Tokyo, Japan) · 2025Article
- Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome.Frontiers in immunology · 2025Article
- Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report.Therapeutic advances in neurological disorders · 2025Article
- Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis.Frontiers in oncology · 2025Article
- Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy.Neurology · 2024Review
- Review
- Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.Clinical case reports · 2024Article
- Current Immunotherapy Treatments of Primary Breast Cancer Subtypes.Biomedicines · 2024Review
- Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn recent years, immune checkpoint inhibitors have been increasingly used in patients with metastatic cancers with favorable oncological outcomes; however, there have also been increasing number of cancer survivors who have developed immune-related adverse events. Little is known about PD-1 inhibitor-associated neuromuscular complications. RECENT
findingsNeuromuscular disorders are the most common neurological complication reported in PD-1 inhibitor-treated patients. Myasthenia gravis, immune-mediated myopathies, and Guillain-Barre syndrome are among commonly reported immune-related neuromuscular complications. HyperCKemia occurs frequently in patients with PD-1 inhibitor-associated myasthenia gravis, indicating coexisting myopathies or myocarditis. Oculobulbar weakness is a unique and common presentation of PD-1 inhibitor-associated immune-mediated myopathies with or without concomitant myasthenia gravis. High-dose steroid monotherapy may be associated with clinical deterioration in some patients with PD-1 inhibitor-associated myasthenia gravis, immune-mediated myopathies, or Guillain-Barre syndrome. PD-1 inhibitor-associated neuromuscular complications have some characteristic features compared to their idiopathic counterparts. Although steroid monotherapy is commonly used in non-neuromuscular autoimmune disorders triggered by anti-PD-1 therapy, this may lead to unfavorable outcomes in some patients with PD-1 inhibitor-associated neuromuscular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.